Journal article
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines
AW Chung, M Ghebremichael, H Robinson, E Brown, I Choi, S Lane, AS Dugast, MK Schoen, M Rolland, TJ Suscovich, AE Mahan, L Liao, H Streeck, C Andrews, S Rerks-Ngarm, S Nitayaphan, MS De Souza, J Kaewkungwal, P Pitisuttithum, D Francis Show all
Science Translational Medicine | Published : 2014
Abstract
The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By contrast, vaccination with VAX003 (consisting of only AIDSVAX B/E) was not protective. Because protection within RV144 was observed in the absence of neutralizing antibody activity or cytotoxic T cell responses, we speculated that the specificity or qualitative differences in Fc-effector profiles of nonneutralizing antibodies may have accounted for the efficacy differences observed between the two trials. We show that the RV144 regimen elicited nonneutralizing antibodies with highly coordinated Fc-mediated effector responses through the sel..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
This work was supported by the US Military HIV Research Program (MHRP) (A.W.C. and G.A.), NIH (R01 AI080289) (G.A.), American Australian Association (Amgen Fellowship) (A.W.C.), National Health and Medical Research Center (APP1036470) (A.W.C.), Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (A.W.C., E.B., I.C., A.-S.D., A.E.M., C.B.-K., M.E.A., and G.A.), and NIH Harvard Center for AIDS Research (P30 AI060354-02) (G.A.).